Daily FNArena News - Small Caps

Aussie biotech junior Bionomics has received positive results from early trials of an anti-anxiety compound and Bell Potter sees enough potential upside to rate the stock a Speculative Buy.

The stockbroker formerly known as Southern Cross Equities (now Bell Potter) has reiterated its Speculative Buy rating on Starpharma.

IT group UXC is looking to divest its Field Services division and stockbroker Moelis suggests this is likely to act as a positive catalyst.

Morgan Stanley suggests the upcoming full year result for ASG Group is likely to act as a positive catalyst for the share price.

Norfolk Group delivered a good quality profit result and with guidance for FY12 viewed as conservative brokers continue to rate the stock as a Buy.

The full year profit result for Programmed Maintenance Services showed a far stronger second half, leading to increased broker confidence of a recovery year for earnings in FY12.

Thorn Group posted a full year profit at the top end of guidance and with further growth from a broader base expected in coming years brokers continue to see value.

Starpharma should generate first revenues from its VivaGel product this year and Southern Cross sees further upside as the company continues to develop its dendrimer technology.

REVA Medical is developing bioresobable stents for treating coronary artery disease and Southern Cross rates the stock a Spec Buy.

Prima Biomed is moving to late stage clinical trials for its CVac cancer vaccine and Southern Cross sees significant upside potential.